Business Wire

Hamad International Airport's Senior Operations Manager appointed as CEO of Ancona International Airport

14.10.2025 09:00:00 CEST | Business Wire | Press Release

Share

Ancona International Airport (“AIA”), a Njord Partners portfolio company, is pleased to announce the appointment of Giorgio Buffa as its new Chief Executive Officer, effective 13 October 2025.

Giorgio Buffa joins Ancona from Doha’s Hamad International Airport, where he was the Senior Operations Manager. He brings over 20 years of dedicated experience in the airport and airline industries, having spent his entire career in aviation. He is recognised for driving operational excellence and pioneering sustainable development at Hamad International Airport, which has, for multiple years, been named the "World's Best Airport" by Skytrax, setting new standards in the airport sector. For the past nine years, he has been instrumental in overseeing key operational functions and successfully navigated the COVID-19 period as well as major events such as the FIFA World Cup. Formerly a pilot with Alitalia and Air One, Giorgio has held various senior leadership roles in airport operations, including Head of Airport Operations at Trapani Airport.

Giorgio succeeds Alex D’Orsogna, who was recently appointed General Director of ENAC (the Italian Civil Aviation Authority) by the Prime Minister. Under Alex’s tenure, Ancona achieved record growth in freight and passenger operations and launched key infrastructure and intermodal projects, firmly establishing the airport as a leading logistics and transport hub in Italy and Europe.

Giorgio’s appointment comes at a time of exciting momentum for AIA, as the airport continues its ambitious strategic transformation, through the establishment of an MRO facility, as well as the two flagship projects: Spaceport (suborbital space flights) and vertiport for VTOLs. Furthermore, Amazon will inaugurate its new logistics hub, the largest in Italy and the second largest in Europe, later this year. Located just 6km from the airport, it positions AIA to benefit from significant cargo volume growth, as well as an overall increase in economic activity in the region.

Giorgio Buffa, incoming AIA CEO, commented: “I am excited to lead Ancona at such a pivotal time of growth and transformation. As an intermodal transport hub, Ancona has immense potential. I look forward to working alongside our talented team and partners to further strengthen and sustainably grow our strategic position as a leader in integrated transport, serving the Marche Region's communities, businesses as well as our international customers.”

Hamish de Run, AIA Chairman, added: “Ancona stands at the forefront of a new era for Italian aviation. I am immensely proud of the progress we have achieved to date. As AIA continues its ambitious journey under Giorgio’s leadership, I am confident AIA will be positioned as the industry standard for excellence.”

Arvid Trolle, Partner at Njord Partners, said: “As we begin this new chapter with Giorgio as CEO, we are confident that his leadership will drive Ancona’s continued growth. I would like to thank Alex for his guidance and dedication during this transformative period. We look forward to supporting Ancona’s future successes and are proud to be part of the journey to position Italy as a leader in European aerospace.”

About Ancona International Airport

Ancona International Airport, known as Marche Airport, is the primary airport serving the Marche region of Italy. As a multi-dimensional airport, it offers both domestic and international flights as well as private jets, connecting the region with major European destinations. Renowned for its operational efficiency and traveler convenience, Ancona International occupies a central position within the regional transportation network, supporting both commercial and leisure travel. Beyond its passenger services, the airport serves as a vital hub for cargo operations, facilitating freight and logistics and is in progress to host an aircraft maintenance, recovery and overhaul (MRO) facility. Additionally, the Airport is building a path in serving as a focal point for various aerospace research and development initiatives, further solidifying its significance in advancing new aviation technologies and innovation. To find out more visit: https://www.ancona-airport.com/en/

About Njord Partners

Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations, its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value.

To find out more visit: https://njordpartners.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014623011/en/

Contacts

Media enquiries: via Camarco
Jennifer Renwick
Letaba Rimell
njord@apcoworldwide.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye